From: The fading of reported effectiveness. A meta-analysis of randomised controlled trials
 | Ranking of model | Effect size measured in absolute terms | Effect size measured in relative terms | ||
---|---|---|---|---|---|
 |  | Variables in model | R2* | Variables in model | R2 |
Pravastatin | 1 | B, Y | 0.8477 | Y, B | 0.2941 |
 | 2 | B, T | 0.8077 | Y, T | 0.2916 |
 | 3 | B, n | 0.8060 | Y, n | 0.2910 |
 | 4 | B | 0.8037 | Y | 0.2873 |
Atorvastatin | 1 | B, T | 0.7473 | T, Y | 0.2014 |
 | 2 | B, Y | 0.6961 | T, B | 0.2001 |
 | 3 | B, n | 0.6960 | T, n | 0.1957 |
 | 4 | B | 0.6959 | T | 0.1882 |
Timolol | 1 | B, Y | 0.5453 | Y, B | 0.2351 |
 | 2 | B, T | 0.4948 | Y, n | 0.2206 |
 | 3 | B, n | 0.4829 | Y, T | 0.1979 |
 | 4 | B | 0.4829 | Y | 0.1958 |
Latanoprost | 1 | B, Y | 0.7958 | B, Y | 0.5636 |
 | 2 | B, T | 0.7798 | B, T | 0.5306 |
 | 3 | B, n | 0.7649 | B, n | 0.5030 |
 | 4 | B | 0.7647 | B | 0.5030 |